
Opinion|Videos|January 29, 2025
Standard of Care in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant intravesical chemotherapy. High-risk cases receive BCG induction/maintenance therapy after TURBT, with close monitoring.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Discuss the current standard of care for patients with low-risk, intermediate-risk, and high-risk NMIBC? What is the role of BCG in these patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
5












